The pace of initial public offerings in the US predictably slowed during the summer, although whether the slowdown was caused by financial market conditions or vacation schedules remains to be seen. Even so, three drug developers spent their summers filing paperwork with the US Securities and Exchange Commission (SEC) in support of future IPOs, each of which could be the first $100m-plus first-time offerings since mid-July.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Redalpine’s $200m VC Fund Backs Tech And Biotech
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.

More from Financing
More from Business
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.